Ifosfamide‐induced encephalopathy and movement disorder

Ames, Bethany; Lewis, Lionel D.; Chaffee, Sara; Kim, Julie; Morse, Richard P.

doi:10.1002/pbc.22361

Cited by 30 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, not surprising, the most common adverse event of the central nervous system identified induced by ifosfamide toxicity was encephalopathy. Unlike the previous report, we did not find any case of ifosfamide-induced hemiballism [4]. It remains to be determined whether the onset of movement disorders precedes the onset encephalopathy or vice versa.…”

Section: Discussioncontrasting

confidence: 60%

Ifosfamide associated myoclonus-encephalopathy syndrome

2011

View full text Add to dashboard Cite

The aim of this study was to investigate the presence of movement disorders associated with ifosfamide toxicity. One of the most common adverse events of ifosfamide treatment is central nervous system toxicity. However, little is known about the occurrence of movement disorders associated with ifosfamide toxicity. We performed a retrospective computer search of the electronic medical records database of the Mayo Clinic, Rochester, MN from 1 January 1997-30 June 2010, using a series of search terms to identify all patients that had been treated with ifosfamide for systemic cancer. Among 400 patients that have ever used ifosfamide, we selected those patients that had any neurological complication in their medical records after the use of ifosfamide. Fifty-two had a neurological complication after ifosfamide administration. The most common neurological complication was encephalopathy that was present in 11 cases (21%). The presence of a movement disorder time locked to the administration of ifosfamide was reported in seven cases (13%). Generalized myoclonus was most common, occurring in four patients while postural tremor was documented in the other three. All patients with myoclonus had asterixis. Four of the patients also had encephalopathy. In six patients the movement disorders resolved within 48 h, spontaneously, after the discontinuation of ifosfamide, while in one case resolved in 24 h after the treatment with methylene blue. Our study demonstrates that although encephalopathy is the most common adverse neurological event associated with ifosfamide toxicity, movement disorders, including generalized myoclonus, asterixis, and postural tremors may also occur. Treatment with methylene blue may be further considered as useful to ameliorate the movement disorders.

show abstract

Section: Discussioncontrasting

confidence: 60%

Ifosfamide associated myoclonus-encephalopathy syndrome

2011

View full text Add to dashboard Cite

show abstract

“…Thus, vitamin B1 (thiamine) plays an essential role in key enzyme of the pentose phosphate pathway and amino acid catabolism [60]. Increases in B1, linked to increased expression of the transporter (THTR2), have been reported in breast cancer, and chemotherapeutic drugs such as 5-fluorouracil (5-FU) result in a thiamine-deficient state [61,62]. The role of thiamine appears to be dose dependent, with low doses serving to promote, but with high doses suppressing proliferation [63].…”

Section: Discussionmentioning

confidence: 99%

Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma

et al. 2019

View full text Add to dashboard Cite

Metabolomics based on untargeted flow infusion electrospray ionization high-resolution mass spectrometry (FIE-HRMS) can provide a snap-shot of metabolism in living cells. Lung Squamous Cell Carcinoma (SCC) is one of the predominant subtypes of Non-Small Cell Lung Cancers (NSCLCs), which usually shows a poor prognosis. We analysed lung SCC samples and matched histologically normal lung tissues from eight patients. Metabolites were profiled by FIE-HRMS and assessed using t-test and principal component analysis (PCA). Differentially accumulating metabolites were mapped to pathways using the mummichog algorithm in R, and biologically meaningful patterns were indicated by Metabolite Set Enrichment Analysis (MSEA). We identified metabolic rewiring networks, including the suppression of the oxidative pentose pathway and found that the normal tricarboxylic acid (TCA) cycle were decoupled from increases in glycolysis and glutamine reductive carboxylation. Well-established associated effects on nucleotide, amino acid and thiol metabolism were also seen. Novel aspects in SCC tissue were increased in Vitamin B complex cofactors, serotonin and a reduction of γ-aminobutyric acid (GABA). Our results show the value of FIE-HRMS as a high throughput screening method that could be exploited in clinical contexts.

show abstract

“…IIE ranges from mild confusion (the most frequent symptom) or somnolence to more severe forms with memory loss, disorientation, hallucinations, seizure, delirium, or, rarely, even coma and death. Cerebellar and cranial nerve dysfunction or other movement disorders have rarely been described (56, 57). Symptoms occur during infusion or after few hours, followed by complete recovery in 20–72 h. Additional treatment generally is not necessary but i.v.…”

Section: Therapy-related Central Neurotoxicity Other Than Presmentioning

confidence: 99%

Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation

et al. 2017

View full text Add to dashboard Cite

Therapy-related neurotoxicity greatly affects possibility of survival and quality of life of pediatric patients treated for cancer. Central nervous system (CNS) involvement is heterogeneous, varying from very mild and transient symptoms to extremely severe and debilitating, or even lethal syndromes. In this review, we will discuss the broad scenario of CNS complications and toxicities occurring during the treatment of pediatric patients receiving both chemotherapies and hematopoietic stem cell transplantation. Different types of complications are reviewed ranging from therapy related to cerebrovascular with a specific focus on neuroradiologic and clinical features.

show abstract

Ifosfamide‐induced encephalopathy and movement disorder

Cited by 30 publications

References 16 publications

Ifosfamide associated myoclonus-encephalopathy syndrome

Ifosfamide associated myoclonus-encephalopathy syndrome

Defining Metabolic Rewiring in Lung Squamous Cell Carcinoma

Central Nervous System Complications in Children Receiving Chemotherapy or Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About